Tcm Biotech International Corp

Capital Structure and Liquidity Tcm Biotech International Corp has a market capitalization of TWD 9.42 billion and a price-to-book ratio of 8.92, indicating a premium valuation relative to its book value. The company maintains a strong liquidity position with a current ratio of 7.47, suggesting ample short-term assets to cover liabilities. However, the company has a negative net cash position after subtracting total debt, which could pose a liquidity risk if not managed. ### Profitability and Returns The company's profitability is modest, with a return on equity (ROE) of 1.82% and a return on assets (ROA) of 1.59%. These figures are below the industry median for pharmaceutical companies, indicating that the company is not generating strong returns relative to its equity and asset base. The operating margin is also low, with operating income of TWD 18.65 million on revenue of TWD 685.49 million, suggesting limited operational efficiency. ### Segments and Geographic Exposure Tcm Biotech International Corp operates in multiple segments, including the development of new medicines for liver disease, the manufacture and sale of dietary supplements and botanical raw materials, and the sale of western medicine and medical equipment. The company's revenue is distributed across domestic and overseas markets, but the report does not provide specific geographic revenue breakdowns. This lack of detail makes it difficult to assess the company's exposure to regional economic conditions. ### Growth Trajectory The company's growth trajectory is uncertain, as the financial data does not provide forward-looking revenue projections. The current FY outlook is not specified, and the next FY direction is also not quantified. The company's capital expenditure is negative, indicating a reduction in investment in physical assets, which could signal a focus on cost control rather than expansion. ### Risk Factors The company faces a medium liquidity risk, as indicated by the negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the near term. The risk assessment does not identify any major credit risks, but the company's modest profitability and low returns could affect its ability to service debt or fund growth initiatives. ### Recent Events The company has not disclosed any recent significant events, such as major filings or transcripts, that would impact its financial position or strategic direction. The analyst estimates suggest a strong buy recommendation, with a mean price target of TWD 194.00, indicating positive sentiment among analysts.